NCT07028775Not yet recruiting
Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
Clinical Application Study and Evaluation of Clopidogrel Resistance-Related Biomarkers in Predicting the Recurrence of Ischemic Events After Cerebral Artery Stenting
Source: ClinicalTrials.gov · Last updated 19 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the clinical significance of clopidogrel resistance-associated biomarkers (TMAO, C1q, and C4BPα) in patients receiving cerebral artery stents, and to develop an integrated predictive model incorporating these novel biomarkers along with CYP2C19 genotyping data for accurate clopidogrel resistance prediction in Chinese populations. By establishing this multidimensional assessment system, we intend to provide reliable risk stratification for post-stenting ischemic events and in-stent restenosis, ultimately facilitating personalized antiplatelet therapy decisions in cerebrovascular interventions. The proposed model may serve as a valuable clinical tool to optimize treatment strategies and improve outcomes for stented patients at risk of clopidogrel resistance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 839 (estimated)
- First submitted
- 21 May 2025
- Start date
- Jun 2025
- Primary completion date
- Apr 2027
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
- Diseases
- Stroke
- NCT number
- NCT07028775
What you commit to
- Study type: Observational
- Planned participants: 839
- From Jun 2025 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cardioembolic stroke (e.g., with atrial fibrillation);
- Embolic stroke of undetermined source (ESUS);
- Perioperative stroke;
- Allergy to clopidogrel or aspirin;
- Bleeding tendency (e.g., thrombocytopenia or active gastrointestinal ulcer);
- History of recurrent miscarriage or current pregnancy;
- Malignancy or life expectancy \<1 year.
Other
- Requiring intravenous thrombolysis (rt-PA, urokinase, alteplase, or tenecteplase);
- Mechanical thrombectomy;
- Current use of anticoagulants (warfarin, rivaroxaban, dabigatran, etc.);
- Severe hepatic or renal dysfunction;
Who the study is looking for
- Age 18-80 years, with ischemic stroke due to atherosclerotic cerebrovascular stenosis;
- Scheduled for cerebral artery stenting with standard dual antiplatelet therapy (aspirin 100 mg/day + clopidogrel 75 mg/day) for ≥3 months.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing First Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.